Clinical Trial Update: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update on managing pyrexia with an IL-6 antibody in BRAF-positive melanoma patients treated with dabrafenib/trametinib; the trial status is termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• IL-6 antibody (pyrexia management)
• Trametinib (trametinib)

Snippet

Sponsor: University of Zurich | Conditions: Pyrexia | Phase 2 | Status: TERMINATED